Jan 24 2022
This article in Blood illustrates the disparity between chromogenic and clot-based factor VIII assays when measuring factor VIII activity produced by hemophilic recipients of gene transfer factor VIII: Rosen S, Tiefenbacker S, Robinson M, et al. Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy. Blood 2020;136:2524–34. Thanks to Dean Willett, Precision BioLogic Inc. for the reference.
Comments (0)
Bleeding Disorders
No comments here.